380 related articles for article (PubMed ID: 27533512)
1. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
2. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
4. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Samaraweera AP; Cohen SN; Akay EM; Evangelou N
Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
Sharim J; Tashjian R; Golzy N; Pouratian N
J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
[TBL] [Abstract][Full Text] [Related]
6. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
7. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
[No Abstract] [Full Text] [Related]
8. Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations.
Schröder K; Finis D; Harmel J; Ringelstein M; Hartung HP; Geerling G; Aktas O; Guthoff R
Mult Scler Relat Disord; 2015 Sep; 4(5):406-408. PubMed ID: 26346788
[TBL] [Abstract][Full Text] [Related]
9. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Walker S; Brew B
J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
[TBL] [Abstract][Full Text] [Related]
10. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
12. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
[TBL] [Abstract][Full Text] [Related]
13. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
Navardi S; Sahraian MA
Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.
Fruschelli M; Capozzoli M; Gelmi MC; Masi G; Annunziata P
Int Ophthalmol; 2019 Apr; 39(4):777-781. PubMed ID: 29500696
[TBL] [Abstract][Full Text] [Related]
15. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
[TBL] [Abstract][Full Text] [Related]
16. Early and recurrent macular oedema in a patient treated with fingolimod.
Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
[No Abstract] [Full Text] [Related]
17. Postoperative cystoid macular oedema in a patient on fingolimod.
Gaskin JC; Coote M
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25969500
[TBL] [Abstract][Full Text] [Related]
18. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
[TBL] [Abstract][Full Text] [Related]
19. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
Hovi A; Airas L
J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
[No Abstract] [Full Text] [Related]
20. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Meissner A; Limmroth V
Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
